Browsing Tag
Intellia Therapeutics
4 posts
Intellia’s $400m OrbiMed facility gains relevance as lonvo-z wins FDA Priority Review
Intellia secured an OrbiMed facility of up to $400 million on September 4 and drew $75 million upfront. Four days later, the FDA accepted lonvo-z for Priority Review with a March 10, 2027 decision date, bringing the next $75 million regulatory tranche into sharper focus.
Why hereditary angioedema could become Intellia Therapeutics’ biggest CRISPR validation test
Find out how Intellia’s lonvo-z Phase 3 data could reshape HAE treatment and investor sentiment around in vivo CRISPR.
Is the FDA’s hold on Intellia a warning sign for in vivo CRISPR delivery across biotech?
Intellia’s nex-z trials face FDA hold after liver safety event. Learn how its extended cash runway to mid-2027 could reshape biotech investor confidence.
Intellia’s Nexiguran Ziclumeran (nex-z) phase 3 trials paused following grade 4 liver toxicity event
Find out why Intellia Therapeutics paused its phase 3 Nexiguran Ziclumeran (nex-z) trials after a severe liver event—and what it means for CRISPR’s future.